Axial Spondyloarthritis Market: How Are IL-23 Inhibitors Entering...

added blog Health

2026-04-09 17:54:49 -

Axial Spondyloarthritis Market: How Are IL-23 Inhibitors Entering the axSpA Pipeline?

IL-23 inhibitor development for axial spondyloarthritis — the investigation of risankizumab (Skyrizi), guselkumab (Tremfya), and other IL-23p19 selective inhibitors for axSpA following their success in psoriatic arthritis and psoriasis — represents the next pipeline wave for axSpA treatment, with the Axial Spondyloarthritis Market reflecting IL-23 inhibitors as an important...

0 Comments 0 Shares 32 Views 0 Reviews